Nasdaq apls.
It is now at its lowest level since June of 2020: 1. That is not a pretty 2-year chart, and investors are inevitably wondering whether the stock can be expected to recover anytime soon, or if it ...
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...
WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...
WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...20 de jul. de 2023 ... As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high ...WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...
WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...
21 февр. 2023 г. ... On today's stock market, APLS stock surged 5.4% to close at 58.50. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices ...
The APLS stock price is -107.15% off its 52-week high price of $94.75 and 56.65% above the 52-week low of $19.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.29 million shares traded. The 3-month trading volume is 3.02 million shares. Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade informationMarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals... Jul 28, 2023 · As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ... Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ... Apellis Pharmaceuticals, Inc. (“Apellis”) (NASDAQ:APLS) recently completed an upsized underwritten public offering of 10062500 shares of its common stock at ...Analyst's Opinion · Consensus Rating. Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to ...Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …APLS GAP FILL APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Underlying @ entry 33.33 I'm a beginner so this is not advice. APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […]Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
Apellis Pharmaceuticals (NASDAQ:APLS) dropped 10% amid a new short report. The short report is apparently from Favus research, according to traders on Wednesday. Details of the short report couldn ...
May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ... Market Activity -> Funds + ETFs After-Hours Quotes See All Market Activity-> News + Insights See All News + Insights-> -> Apellis Pharmaceuticals, Inc. Common Stock P/E & …The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
08/15/2022. Option Execute. Direct. 12,500. $15.09. 55,407. Back to APLS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and ...
3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ...The APLS shares have gain 13.10% over the last week, with a monthly amount glided 10.71%, and seem to be holding up well over. A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $53.87, up 7.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The APLS shares …Find the latest Insider Activity data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...23 de ago. de 2023 ... Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 35% in Wednesday's deals after last night updating investors on an ongoing safety ...WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...
The US FDA has extended by an undetermined period its review of an sNDA from Apellis Pharmaceuticals (NASDAQ:APLS) for Empaveli Injector (pegcetacoplan). The original action date was March 15.Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...The chart below shows the one year performance of APLS shares: Looking at the chart above, APLS's low point in its 52 week range is $42.15 per share, with $94.75 as the 52 week high point — that ...Instagram:https://instagram. news on amd stockstock price isrgigm etfcan you buy a house with a 600 credit score Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ... biggest gainers premarketfinmy Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2 ... group expro hapabapa. Apellis Pharmaceuticals ( NASDAQ: APLS) won the FDA approval for its marketing application for lead asset pegcetacoplan on Friday as a treatment for geographic atrophy (GA) secondary to ...WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.